









Markets
/
Stocks
/
nasdaq-ivvd
/

Invivyd Inc

IVVD

1.540USD

+0.020+1.32%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

185.02MMarket Cap

LossP/E TTM



Invivyd Inc

1.540

+0.020+1.32%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Invivyd Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Invivyd Inc's Score

Industry at a Glance

Industry Ranking

75 / 159

Overall Ranking

214 / 4615

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.333

Target Price

+382.46%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Invivyd Inc Highlights

StrengthsRisks

Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Company’s first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Growing

The company is in a growing phase, with the latest annual income totaling USD 25.38M.

Undervalued

The company’s latest PE is -1.68, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 127.24M shares, increasing 22.21% quarter-over-quarter.

Held by Lee Ainslie

Star Investor Lee Ainslie holds 10.23M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.87.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 7.73, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 11.79M, representing a year-over-year increase of 420.58%, while its net profit experienced a year-over-year increase of 68.97%.

Score

Industry at a Glance

Previous score

7.73

Change



Financials

6.60

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.71

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.10

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Invivyd Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 7.58, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -1.68, which is -86.87% below the recent high of -0.22 and -65.83% above the recent low of -2.78.

Score

Industry at a Glance

Previous score

7.58

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Invivyd Inc is 10.00, with a high of 10.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.333

Target Price

+382.46%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Invivyd Inc

IVVD

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 6.80, which is lower than the Pharmaceuticals industry's average of 6.90. Sideways: Currently, the stock price is trading between the resistance level at 2.14 and the support level at 1.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.77

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.170

Neutral

RSI(14)

45.758

Neutral

STOCH(KDJ)(9,3,3)

14.807

Oversold

ATR(14)

0.262

Low Volatility

CCI(14)

-110.050

Sell

Williams %R

81.818

Oversold

TRIX(12,20)

0.803

Sell

StochRSI(14)

45.936

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.566

Sell

MA10

1.812

Sell

MA20

1.822

Sell

MA50

1.467

Buy

MA100

1.100

Buy

MA200

0.977

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 60.77%, representing a quarter-over-quarter decrease of 42.47%. The largest institutional shareholder is Steven Cohen, holding a total of 16.73M shares, representing 7.99% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

24.27M

RA Capital Management, LP

17.12M

Point72 Asset Management, L.P.

Star Investors

16.73M

Mithril Capital Management LLC

11.24M

Royan (Ajay G.)

11.21M

Maverick Capital, Ltd.

Star Investors

10.23M

-6.66%

M28 Capital Management LP

9.25M

Deep Track Capital LP

8.59M

-11.69%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 1.27, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.67. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.